ProCE Banner Activity

STAR*D and Beyond: Current and Upcoming Adjunctive Therapies for Depression

Clinical Thought

In this ClinicalThought, the author discusses the evolution of major depressive disorder treatment from STAR*D and current treatment steps to what has become available more recently and what is on the horizon.

Released: October 23, 2024

Expiration: October 22, 2025

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc. and Intra-Cellular Therapies, Inc.

AbbVie Inc.

Intra-Cellular Therapies, Inc.

Faculty Disclosure

Primary Author

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Akilli, Alkermes, Angelini, Axsome, Aytu, Biogen, Boehringer Ingelheim, Cerevel, Corium, Eisai, Intracellular, Ironshore, Janssen, Liva Nova, Lumos Labs, Lundbeck, Manus, Neurocrine, Noven, Otsuka, Redax, Relmada, Revibe, Roche, Sage, Sirona, Sky Therapeutics, Sunovion, Supernus, Takeda, Teva, Tris; researcher: AbbVie, Acadia, Alkermes, Akilli, Alto Therapeutics, Autobahn, Avanir, Axsome, Boehringer Ingelheim, Cingulate, Click Therapeutics, Compass, Corium, Emalex, Idorsida, Intracellular, Janssen, Karuna, Lumos Labs, Medgenics, Neumora, Neurocrine, NLS-1 Pharma, Redax, Relmada, Roche, Sage, Sirtsei, Sumitomo, Sunovion, Supernus, Takeda, Teva.